EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants

Rabab Batool, Ran Wang, Hala Obeid, Tobias R Kollmann, Joanne M Langley, Pascal M Lavoie, Bahaa Abu-Raya

JAMA Pediatrics · 01.11.2026 · 180 (11) · 1213

DOI: 10.1001/jamapediatrics.2026.4074 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JAMA Pediatrics, erschienen am 01.11.2026. Verfasst von Rabab Batool und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human, Viral Fusion Proteins. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The respiratory syncytial virus (RSV) bivalent prefusion F protein vaccine (RSVpreF) administered during pregnancy has demonstrated efficacy in protecting infants against early-life RSV disease in the pivotal clinical trial.

Objective

To conduct a systematic review and meta-analysis to synthesize real-world evidence on the effectiveness of RSVpreF in preventing RSV-associated lower respiratory tract infection (LRTI) in infants. Data Sources PubMed, Scopus, and Europe PMC were searched from January 1, 2020, through January 30, 2026. Study Selection A total of 1144 studies were initially identified. Eligible were nonrandomized studies reporting the effectiveness of RSVpreF vaccine in pregnancy in the prevention of RSV-associated LRTI in infants. Data Extraction and Synthesis All studies were screened independently by 2 reviewers. Data were extracted on RSV-associated outcomes among infants born to women who received RSVpreF vaccination during pregnancy and infants born to unvaccinated women. Main Outcomes and Measures The primary outcome was RSV-associated LRTI hospitalization. Odds ratios (ORs) were pooled using random-effects meta-analysis with the Hartung-Knapp adjustment and Sidik-Jonkman estimator. Vaccine effectiveness against RSV-associated LRTI hospitalization was calculated as (1 − OR) × 100% and assessed in infants from birth to age 3 months and from birth to 6 months, separately. The limited available data precluded meta-analysis of effectiveness against the secondary outcomes of RSV-associated emergency department visits, intensive care unit admissions, and death.

Results

A total of 7 studies were included, comprising 7112 infants, of whom 2684 were born to vaccinated mothers. The studies collected data from January 2024 through April 2025 from Argentina, the UK, and the US. Pooled vaccine effectiveness against RSV-associated LRTI hospitalization was 82% (95% CI, 81%-82%; 3 studies, 4397 participants; I 2 = 0%) in infants from birth to 3 months and 78% (95% CI, 70%-84%; 6 studies, 3008 participants; I 2 = 18.7%) in infants from birth to 6 months, when mothers were vaccinated 14 days or more before delivery. Conclusions and Relevance The results of this systematic review and meta-analysis suggest that postimplementation data support the effectiveness of RSVpreF in pregnancy for the prevention of RSV-associated LRTI hospitalization during the first 6 months of life. The results support the introduction of RSVpreF into routine antenatal immunization programs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesRespiratory Syncytial Virus, HumanViral Fusion ProteinsPregnancy Complications, InfectiousHumansFemalePregnancyInfantInfant, Newborn

Substanzen

Respiratory Syncytial Virus VaccinesViral Fusion Proteins

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre and the Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.
  • Departments of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Laboratory of Infection and Virology, Beijing Pediatric Research Institute, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
  • Departments of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.

Zitieren

APA

Batool, R., Wang, R., Obeid, H., Kollmann, T. R., Langley, J. M., Lavoie, P. M., & Abu-Raya, B. (2026). RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants. JAMA Pediatrics, 180(11), 1213. https://doi.org/10.1001/jamapediatrics.2026.4074

Vancouver

Batool R, Wang R, Obeid H, Kollmann TR, Langley JM, Lavoie PM, et al. RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants. JAMA Pediatrics. 2026;180(11):1213. doi:10.1001/jamapediatrics.2026.4074

BibTeX
@article{Batool2026,
  author = {Batool, Rabab and Wang, Ran and Obeid, Hala and Kollmann, Tobias R and Langley, Joanne M and Lavoie, Pascal M and Abu-Raya, Bahaa},
  title = {RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants},
  journal = {JAMA Pediatrics},
  year = {2026},
  volume = {180},
  number = {11},
  pages = {1213},
  doi = {10.1001/jamapediatrics.2026.4074}
}
Kostenlos starten →